Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer

[1]  M. Lux,et al.  Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer , 2018, Geburtshilfe und Frauenheilkunde.

[2]  M. Bani,et al.  Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer , 2018, BMC Cancer.

[3]  S. Loi,et al.  Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer , 2018, The New England journal of medicine.

[4]  M. Lux,et al.  Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer , 2018, Geburtshilfe und Frauenheilkunde.

[5]  S. Loi,et al.  Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer , 2018, Journal of the National Cancer Institute.

[6]  L. Chow,et al.  Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. , 2018, The Lancet. Oncology.

[7]  P. Fasching,et al.  Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Virginia G Kaklamani,et al.  Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.

[9]  Tanja Fehm,et al.  BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Lux,et al.  Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers , 2018, Geburtshilfe und Frauenheilkunde.

[11]  M. Goetz,et al.  MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Neven,et al.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Boros,et al.  Intratumoral Heterogeneity for Ki-67 Index in Invasive Breast Carcinoma: A Study on 131 Consecutive Cases , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[14]  Yul Ri Chung,et al.  A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method , 2017, PloS one.

[15]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[16]  P. Diest,et al.  Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours , 2016, Histopathology.

[17]  L. V. van't Veer,et al.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.

[18]  Atsushi Arakawa,et al.  Ki67 Heterogeneity in Estrogen Receptor–Positive Breast Cancers , 2016, International journal of surgical pathology.

[19]  Virginia G Kaklamani,et al.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.

[20]  F. André,et al.  Ki67—no evidence for its use in node-positive breast cancer , 2015, Nature Reviews Clinical Oncology.

[21]  H Dienemann,et al.  Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role , 2014, British Journal of Cancer.

[22]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[23]  Aiko Sueta,et al.  Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes? , 2014, Surgery.

[24]  E. Paci,et al.  Ki67 in breast cancer: a useful prognostic marker? , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  H Tesch,et al.  Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  H. Sasano,et al.  Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy , 2013, Breast Cancer Research and Treatment.

[27]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  M. Bani,et al.  Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis , 2013, Breast Cancer Research and Treatment.

[29]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[31]  Peter A Fasching,et al.  Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment , 2011, BMC Cancer.

[32]  J. Cuzick,et al.  Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Bani,et al.  Quality Assured Health Care in Certified Breast Centers and Improvement of the Prognosis of Breast Cancer Patients , 2011, Oncology Research and Treatment.

[34]  M. Dowsett,et al.  Comparative validation of the SP6 antibody to Ki67 in breast cancer , 2010, Journal of Clinical Pathology.

[35]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[36]  Lajos Pusztai,et al.  Gene-expression signatures in breast cancer. , 2009, The New England journal of medicine.

[37]  J. Dering,et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.

[38]  Kyounghwa Bae,et al.  MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[40]  M. Bani,et al.  Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. , 2009, Breast.

[41]  John M S Bartlett,et al.  Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  U. Capitanio,et al.  Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. , 2009, Journal of the National Cancer Institute.

[43]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[44]  Norman Wolmark,et al.  Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[46]  G. Cserni,et al.  Different Methods of Pretreatment Ki-67 Labeling Index Evaluation in Core Biopsies of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Their Relation to Response to Therapy , 2014, Pathology & Oncology Research.

[47]  B. A. Carter,et al.  Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group , 2012 .

[48]  D. Cutter,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.